High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study
High-dose supplements of thiamine prevent the development of microalbuminuria in experimental diabetes. The aim of this pilot study was to assess whether oral supplements of thiamine could reverse microalbuminuria in patients with type 2 diabetes.
Type 2 diabetic patients (21 male, 19 female) with microalbuminuria were recruited at the Diabetes Clinic, Sheikh Zayed Hospital, Lahore, Pakistan, and randomised to placebo and treatment arms. Randomisation was by central office in sequentially numbered opaque, sealed envelopes. Participants, caregivers and those assessing the outcomes were blinded to group assignment. Patients were given 3 × 100 mg capsules of thiamine or placebo per day for 3 months with a 2 month follow-up washout period. The primary endpoint was change in urinary albumin excretion (UAE). Other markers of renal and vascular dysfunction and plasma concentrations of thiamine were determined.
UAE was decreased in patients receiving thiamine therapy for 3 months with respect to baseline (median −17.7 mg/24 h; p < 0.001, n = 20). There was no significant decrease in UAE in patients receiving placebo after 3 months of therapy (n = 20). UAE was significantly lower in patients who had received thiamine therapy compared with those who had received placebo (30.1 vs 35.5 mg/24 h, p < 0.01) but not at baseline. UAE continued to decrease in the 2 month washout period in both groups, but not significantly. There was no effect of thiamine treatment on glycaemic control, dyslipidaemia or BP. There were no adverse effects of therapy.
In this pilot study, high-dose thiamine therapy produced a regression of UAE in type 2 diabetic patients with microalbuminuria. Thiamine supplements at high dose may provide improved therapy for early-stage diabetic nephropathy.
Trial registration: CTRI (India) CTRI/2008/091/000112
Funding: Pakistan Higher Education Commission
- Donnelly R, Emslie-Smith AM, Gardner ID, Morris AD (2000) ABC of arterial and venous disease—vascular complications of diabetes. BMJ 320:1062–1066 CrossRef
- Thornalley PJ (2005) The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Res 1:287–298 CrossRef
- Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high dose thiamine and benfotiamine. Diabetes 52:2110–2120 CrossRef
- Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ (2004) High dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 47:2235–2246 CrossRef
- Thornalley PJ, Babaei-Jadidi R, Al Ali H et al (2007) High prevalence of low plasma thiamine concentration in diabetes linked to marker of vascular disease. Diabetologia 50:2164–2170 CrossRef
- Sasso FC, Carbonara O, Persico M et al (2002) Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care 25:1909–1913 CrossRef
- Andersen S, Brochner-Mortensen J, Parving HH (2003) Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 26:3296–3302 CrossRef
- Zandbergen AAM, Baggen MGA, Lamberts SWJ, Bootsma AH, de Zeeuw D, Ouwendijk RJT (2003) Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. Ann Intern Med 139:90–96
- Toyoda M, Najafian B, Kim Y, Caramori ML, Mauer M (2007) Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 56:2155–2160 CrossRef
- Finglas PM (1993) Thiamin. Int J Vitam Nutr Res 63:270–274
- High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study
Volume 52, Issue 2 , pp 208-212
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Diabetic complications
- Diabetic nephropathy
- Type 2 diabetes
- Industry Sectors
- Author Affiliations
- 1. Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, University Hospital, Clifford Bridge Road, Coventry, CV2 2DX, UK
- 2. Department of Pharmacology, Sheikh Zayed Federal Postgraduate Medical Institute, Sheikh Zayed Hospital, Lahore, Pakistan
- 3. Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan
- 4. School of Biological Sciences, University of the Punjab, Lahore, Pakistan
- 5. Department of Nephrology, Division of Medicine, Sheikh Zayed Federal Postgraduate Medical Institute, Lahore, Pakistan